Fibroblast growth factor 2 (FGF2) is a ubiquitously expressed pleiotropic growth factor with many recognised cellular targets and tissue effects. Its role in articular chondrocytes and mesenchymal cells has been extensively studied, but published data are plagued by apparent contradiction and inconsistency. The paper reported by Yan and colleagues in the previous issue of *Arthritis Research & Therapy* proposes that differences in responses to FGF2 are most likely due to changes in the balance between the two major articular cartilage FGF receptors, FGFR1 and FGFR3. They show that the catabolic and anti-anabolic effects of FGF2 are mediated primarily through FGFR1 whereas the beneficial effects are through FGFR3. This balance is dynamic and is altered in disease and following growth factor stimulation in vitro.

Our own studies have demonstrated that FGF2 is stored within the pericellular matrix of chondrocytes attached to the heparan sulphate chains of perlecan [4]. This pool of growth factor is liberated upon injury or mechanical compression of the matrix [5]. We demonstrated that, at least in young mice, the overall effect of FGF2 in the joint is benign. Indeed, mice lacking FGF2 (FGF2 null mice) developed accelerated osteoarthritis (with age and following surgical joint destabilisation), and this could be reversed by delivery of subcutaneous recombinant FGF2 [6]. When gene expression analysis was performed in FGF2 null joints after induction of osteoarthritis, there was a super-induction of ADAMTS5 mRNA, suggesting that FGF2 normally suppresses ADAMTS5. This was consistent with the ability of FGF2 to suppress interleukin-1-driven aggrecanase activity in normal human articular cartilage explants [7]. These persuasive anti-catabolic activities of FGF2 could well be dependent upon differences in the balance of FGFRs in these tissues, although it is also worth noting that in vivo many other cells within the joint respond to FGF2 (besides chondrocytes) and these could be contributing to the increased disease seen in FGF2 null mice. All the same, these studies alert us to the possibility that receptor expression differs between different tissues, ages of tissue and possibly even species.

The authors also make the interesting observation that the FGFR balance is dynamic. FGF2 itself is able to suppress the expression of FGFR3, whilst bone morphogenetic protein (BMP7) is able to augment expression. This does raise the question as to whether receptor expression is significantly altered when cartilage is explanted and cells are isolated. As FGF2 itself is released upon explantation of cartilage [5], this process may affect...
the balance of FGFRs in the resulting assay material, perhaps leading to skewing of the natural balance of receptors and tending towards a more catabolic phenotype in cultured cells/explants in vitro. It is not known whether FGF18 and BMP7 are also endogenous pericellular matrix-bound proteins, and whether they too are liberated in response to injury. FGF18 has been shown to bind the core protein of perlecan in vitro [8] and it is able to form FGFR3-activating complexes with chondrocyte-derived perlecan [9]. BMP7 is made by chondrocytes and is known to bind to heparan sulphates and fibrillin, and thus may also be bound within the pericellular matrix [10]. The controlled release of these factors within the immediate vicinity of the cell surface could, like FGF2, represent a rapid and efficient way of controlling chondrocyte responses.

The question of whether the FGFR balance changes with age and with disease is an interesting and important one. Yan and colleagues show that there is a significant decrease in FGFR3 expression in human osteoarthritis cartilage compared to tissue from normal post mortem samples, which suggests that release of pericellular FGF2 in diseased cartilage may lead to predominantly catabolic effects and the benefits of exogenous FGF18 will no longer be realised. The extent to which this will limit the utility of FGF18 treatment in human disease will be disclosed in due course when the Merck Serono trial has been completed. In the meanwhile, an important focus will be to develop strategies that augment FGFR3 levels within diseased tissues in order to potentiate the beneficial effects of all FGF family members.

**Abbreviations**

ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs; BMP, bone morphogenetic protein; FGF, fibroblast growth factor; FGFR, FGF receptor.

**Competing interests**

The author declares that she has no competing interests.

**Published:** 30 September 2011

**References**


DOI:10.1186/ar3447

Cite this article as: Vincent TL: Fibroblast growth factor 2: good or bad guy in the joint? *Arthritis Research & Therapy* 2011, 13:127.